Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact?

Gynecological Endocrinology

Volumn 26, Issue 9, 2010, Pages 698-703

  Christopoulos, Panagiotis ^a   Mastorakos, George ^a   Gazouli, Maria ^a   Deligeoroglou, Efthymios ^a   Katsikis, Ilias ^b   Diamanti Kandarakis, Evanthia ^a   Panidis, Dimitrios ^b   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

genes; insulin; IRS 1 Gly972Arg; IRS 2 Gly1057Asp; PCOS; polymorphism; resistance

Indexed keywords

DNA; FOLLITROPIN; GLUCOSE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LUTEINIZING HORMONE; PROLACTIN;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLITROPIN BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; GREECE; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ADULT; AMINO ACID SUBSTITUTION; ARGININE; ASPARTIC ACID; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLYCINE; GREECE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 77955811109     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003649823     Document Type: Article

References (27)

1. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322-353.
2. Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334: 777-783.
3. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol EndocrinolMetab 2001;281: E392-E399.
4. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001;15:2099-2111.
5. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, Sakoda H, Onishi Y, Inukai K, Anai M, Fukushima Y, et al. 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 1997;272:25267-25274.
6. Garcia P, Shoelson SE, George ST, Hinds DA, Goldberg AR, Miller WT. Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro. J Biol Chem 1993;268:25146-25151.
7. Yoshimura R, Araki E, Ura S, Todaka M, Tsuruzoe K, Furukawa N, Motoshima H, Yoshizato K, Kaneko K, Matsuda K, et al. Impact of natural IRS-1 mutations on insulin signals: mutations of IRS-1 in the PTB domain and near SH2 protein binding sites result in impaired function at different steps of IRS-1 signaling. Diabetes 1997;46:929-936.
8. Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998;145:103-110.
9. El Mkadem SA, Lautier C, Macari F, Molinari N, Lefebvre P, Renard E, Gris JC, Cros G, Daures JP, Bringer J, et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001;50:2164-2168.
10. Villuendas G, Botella-Carretero JI, Roldán B, Sancho J, Escobar-Morreale HF, San Millán JL. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod 2005;20:3184-3191.
11. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and-2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4297-4300.
12. Sir-Petermann T, Pérez-Bravo F, Angel B, Maliqueo M, Calvillan M, Palomino A. G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologia 2001;44:1200-1201.
13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
14. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
15. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:341-359. (Pubitemid 29242717)
16. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002;77:919-927.
17. Morley JE, Patrick P, Perry HM IIIrd. Evaluation of assays available to measure free testosterone. Metabolism 2002;51: 554-559.
18. van Dam RM, Hoebee B, Seidell JC, Schaap MM, Blaak EE, Feskens EJ. The insulin receptor substrate-1 Gly972Arg polymorphism is not associated with Type 2 diabetes mellitus in two population-based studies. Diabet Med 2004;21:752-758.
19. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
20. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
21. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116. (Pubitemid 27287569)
22. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001;86:2027-2031.
23. Wu X, Sallinen K, Anttila L, Mäkinen M, Luo C, Pöllänen P, Erkkola R. Expression of insulin-receptor substrate-1 and-2 in ovaries from women with insulin resistance and from controls. Fertil Steril 2000;74:564-572.
24. Witchel SF, Smith R, Tomboc M, Aston CE. Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil Steril 2001;75:724-730.
25. Ibáñez L, Marcos MV, Potau N, White C, Aston CE, Witchel SF. Increased frequency of the G972R variant of the insulin receptor substrate-1 (irs-1) gene among girls with a history of precocious pubarche. Fertil Steril 2002;78:1288-1293.
26. Baba T, Endo T, Sata F, Honnma H, Kitajima Y, Hayashi T, Manase K, Kanaya M, Yamada H, Minakami H. et al. Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population. Life Sci 2007;81:850-854.
27. Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, Wallwiener D, Stumvoll M, Häring HU, Fritsche A. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2005;113:275-281.